Skip to content
ImageTypesTitleLegacy AuthorsLinkhf:tax:medical_library_typehf:tax:medical_library_author
Lola for the treatment of HE in cirrhosis:novel insights and translation to clinic
Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles
Impact of Hepatic Encephalopathy in Cirrhosis on Quality of Life Issues
Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology
Pharmacokinetic and Pharmacodynamic Properties of l Ornithine l Aspartate (LOLA) in Hepatic Encephalopathy
l-Ornithine l-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta Analyses
l-Ornithine l-Aspartate (LOLA) as a Novel Approach for Therapy of Non alcoholic Fatty Liver Disease
Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease
Efficacy of L-Ornithine L-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials
L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Evidence for Novel Hepatoprotective Mechanisms
L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle
L-ornithine L-aspartate for the Treatment of Sarcopenia in Cirrhosis: Potential Impact on the Outcome of Liver Transplantation
Randomized controlled trial comp aring lactulose , probiotics and LOLA in minimal hepatic encephalopathy (MHE)
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers
Oral L-ornithine-L-aspartate in minimal hepatic encephalopathy: a randomized, double blind, placebo-controlled trial
LOLA vs lactulose to improve hepatic encephalopathy and reduce hospital stay
Oral LOLA improves health-related quality of life in cirrhotic patients with HE